Gene therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gene therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote ()	11/22/1999 10:09:00 AM
From: scaram(o)uche	Read Replies (1) of 319

SEATTLE, Nov 22, 1999 /PRNewswire via COMTEX/ -- Targeted Genetics Corp. (Nasdaq: TGEN) today issued a statement as a result of recent media coverage regarding early clinical investigations of adenovirus as a vector for gene therapy. Targeted Genetics wishes to clarify that the company's viral gene delivery platforms utilize vectors derived from Adeno-Associated Virus (AAV), a gene delivery vehicle with significant differences from adenovirus vectors. The company is making this clarification due to the similarity in the names of adenovirus and adeno-associated virus. (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next